am 251 has been researched along with Developmental Disabilities in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rubino, T | 1 |
| Prini, P | 1 |
| Piscitelli, F | 1 |
| Zamberletti, E | 1 |
| Trusel, M | 1 |
| Melis, M | 1 |
| Sagheddu, C | 1 |
| Ligresti, A | 1 |
| Tonini, R | 1 |
| Di Marzo, V | 1 |
| Parolaro, D | 1 |
1 other study available for am 251 and Developmental Disabilities
| Article | Year |
|---|---|
Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex.
Topics: Age Factors; Animals; Cannabinoid Receptor Agonists; Cyclohexanols; Developmental Disabilities; Dizo | 2015 |